Title: High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver
transplantation and the role of controlled attenuation parameter
Version: 1 Date: 26 Apr 2023
Reviewer's report:
This study validated the use of CAP measurement in post-transplant graft steatosis and the
prevalence of de novo graft steatosis and MAFLD after LT in Chinese patients was determined.
The method used in the study is reliable and the results have certain clinical practical value. I
have several suggestions or concerns as follows.
1. The title doesn’t accurately represent the main content of the study. CAP should be involved
in the title.
2. A detailed structured Inclusion and Exclusion Criteria should be provided.
3. Continuous variables should be tested for normality first, and then the appropriate presentation
and statistical method should be selected based on the results.
4. Whether the P-value is a one-sided or two-sided test needs to be specified.
5. Can the combination of CAP with other MAFLD indicators enhance the ability to predict
fatty liver after liver transplantation.
6. Whether CAP results can facilitate effective clinical interventions needs to be discussed.
Title: High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver
transplantation and the role of controlled attenuation parameter
Version: 1 Date: 26 Apr 2023
Reviewer's report:
This study validated the use of CAP measurement in post-transplant graft steatosis and the
prevalence of de novo graft steatosis and MAFLD after LT in Chinese patients was determined.
The method used in the study is reliable and the results have certain clinical practical value. I
have several suggestions or concerns as follows.
1. The title doesn’t accurately represent the main content of the study. CAP should be involved
in the title.
2. A detailed structured Inclusion and Exclusion Criteria should be provided.
3. Continuous variables should be tested for normality first, and then the appropriate presentation
and statistical method should be selected based on the results.
4. Whether the P-value is a one-sided or two-sided test needs to be specified.
5. Can the combination of CAP with other MAFLD indicators enhance the ability to predict
fatty liver after liver transplantation.
6. Whether CAP results can facilitate effective clinical interventions needs to be discussed.
Please review this paper.
user
Title: High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver
transplantation and the role of controlled attenuation parameter
Version: 1 Date: 26 Apr 2023
Reviewer's report:
This study validated the use of CAP measurement in post-transplant graft steatosis and the
prevalence of de novo graft steatosis and MAFLD after LT in Chinese patients was determined.
The method used in the study is reliable and the results have certain clinical practical value. I
have several suggestions or concerns as follows.
1. The title doesn’t accurately represent the main content of the study. CAP should be involved
in the title.
2. A detailed structured Inclusion and Exclusion Criteria should be provided.
3. Continuous variables should be tested for normality first, and then the appropriate presentation
and statistical method should be selected based on the results.
4. Whether the P-value is a one-sided or two-sided test needs to be specified.
5. Can the combination of CAP with other MAFLD indicators enhance the ability to predict
fatty liver after liver transplantation.
6. Whether CAP results can facilitate effective clinical interventions needs to be discussed.
assistant